DEB-TACE治疗肝细胞癌的疗效及安全性观察  

Observation on efficacy and safety of DEB-TACE in the treatment of hepatocellular carcinoma

作　　者：徐明洲[1] 何明[2] 范小斌[1] XU Ming-zhou;HE Ming;FAN Xiao-bin(Interventional Department,The First Affiliated Hospital of Nanyang Medical College,Nanyang 473058,China)

机构地区：[1]南阳医学高等专科学校第一附属医院介入科,473058 [2]南阳医学高等专科学校第一附属医院消化内科,473058

出　　处：《中国现代药物应用》2024年第12期53-56,共4页Chinese Journal of Modern Drug Application

基　　金：南阳市科技计划项目(项目编号:KJGG072)项目名称:DTACE-中应用载药微球治疗肝细胞癌的疗效及安全性观察。

摘　　要：目的探讨载药微球经动脉化疗栓塞术(DEB-TACE)治疗肝细胞癌的疗效及安全性。方法64例肝细胞癌患者,按不同治疗方案分为观察组和对照组,各32例。观察组接受DEB-TACE治疗,对照组采用常规经动脉化疗栓塞术(CTACE)治疗。比较两组患者的临床效果、术后肝功能指标[白蛋白(ALB)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、直接胆红素(DBIL)]、术后不良反应发生率。结果观察组客观缓解率为68.75%、疾病控制率为93.75%,均显著高于对照组的43.75%、75.00%(P<0.05)。观察组术后ALB为(31.96±3.92)g/L,ALT为(140.82±38.17)U/L,AST为(86.52±16.97)U/L,TBIL为(35.12±8.28)μmol/L,DBIL为(16.48±8.41)μmol/L;对照组术后ALB为(32.82±3.67)g/L,ALT为(131.06±29.42)U/L,AST为(78.16±18.59)U/L,TBIL为(34.96±7.59)μmol/L,DBIL为(17.43±9.15)μmol/L;两组术后ALB、ALT、AST、TBIL、DBIL水平比较差异不存在统计学意义(P>0.05)。两组术后血压升高、乏力、消化道反应、发热发生率比较差异不存在统计学意义(P>0.05)。结论DEB-TACE治疗肝细胞癌的效果理想,且不会增加不良反应,其安全有效,值得推广。Objective To explore the efficacy and safety of drug-eluting beads transarterial chemoembolization(DEB-TACE)in the treatment of hepatocellular carcinoma.Methods 64 patients with hepatocellular carcinoma were divided into an observation group and a control group,with 32 cases in each group.The observation group received DEB-TACE treatment,and the control group received conventional transarterial chemoembolization(CTACE)treatment.Both groups were compared in terms of clinical effects,postoperative liver function indexes[albumin(ALB),alanine transaminase(ALT),aspartate transaminase(AST),total bilirubin(TBIL),direct bilirubin(DBIL)]and incidence of postoperative adverse reactions.Results The objective remission rate and disease control rate of the observation group were 68.75%and 93.75%,which were significantly higher than 43.75%and 75.00%of the control group(P<0.05).In the observation group,ALB,ALT,AST,TBIL and DBIL were(31.96±3.92)g/L,(140.82±38.17)U/L,(86.52±16.97)U/L,(35.12±8.28)μmol/L and(16.48±8.41)μmol/L.In the control group,ALB,ALT,AST,TBIL and DBIL were(32.82±3.67)g/L,(131.06±29.42)U/L,(78.16±18.59)U/L,(34.96±7.59)μmol/L and(17.43±9.15)μmol/L.There was no significant difference in postoperative ALB,ALT,AST,TBIL and DBIL between the two groups(P>0.05).There was no significant difference in the incidence of postoperative elevated blood pressure,fatigue,digestive tract reaction and fever between the two groups(P>0.05).Conclusion DEB-TACE has ideal in the treatment of hepatocellular carcinoma without increasing adverse reactions.It is safe and effective and is worth promoting.

关 键 词：载药微球 经动脉化疗栓塞术 肝细胞癌 疗效 安全性 

分 类 号：R735.7[医药卫生—肿瘤]